A Phase 1/2 interventional study of Diazepam Nasal Spray [Valtoco] in Epilepsy, sponsored by Neurelis, Inc.. Completed at 13 sites in United States. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Neurelis, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing diazepam in Epilepsy — none open to participants now, none under way, none of them phase 3. Diazepam · Epilepsy.
Among the 10 studies testing diazepam in Epilepsy, this one is the 7th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1/2, and was the 9th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 10 studies testing diazepam in Epilepsy is open now. The open studies under Epilepsy, anywhere →
Diazepam: first FDA approval 1963 (VALIUM). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 3
First in 1995; this study’s year is marked. 1 started in 2021.
This study's enrollment of 36 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 68 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
Neurelis, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Neurelis, Inc. has 3 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing diazepam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety period in pediatric epilepsy subjects age 2 to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
Drug: Diazepam Nasal Spray [Valtoco]
5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
Maximum Plasma Concentration (Cmax) of Diazepam After Intranasal VALTOCO Administered to Subjects With Epilepsy 2 to 5 Years of Age
Pharmacokinetic levels of diazepam
Time frame: 0-6 hours
| Milestone | Valtoco In Pediatric Subjects With Epilepsy |
|---|---|
| Started | 36 |
| Valtoco 10mg | 29 |
| Valtoco 5mg | 3 |
| Valtoco 15mg | 4 |
| Completed | 31 |
| Not completed | 5 |
Pharmacokinetic levels of diazepam
| Cmax (ng/ml) | Valtoco 5mg 2 to 3 Years Old | Valtoco 10mg 2 to 3 Years Old | Valtoco 10mg 4 to 5 Years Old | Valtoco 15mg 4 to 5 Years Old |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Diazepam After Intranasal VALTOCO Administered to Subjects With Epilepsy 2 to 5 Years of Age | 94.34 ± 60.29 | 269.25 ± 258.77 | 279.91 ± 198.58 | 243.07 ± 249.44 |
Collected over 180 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valtoco 5mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Valtoco 10mg | 0/29 (0%) | 6/29 (20.7%) | 18/29 (62.1%) |
| Valtoco 15mg | 0/4 (0%) | 2/4 (50%) | 3/4 (75%) |
| Event | Valtoco 5mg | Valtoco 10mg | Valtoco 15mg |
|---|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/29 | 0/4 |
| PneumoniaInfections and infestations | 1/3 | 0/29 | 0/4 |
| SeizureNervous system disorders | 0/3 | 2/29 | 1/4 |
| pneumothoraxRespiratory, thoracic and mediastinal disorders | 0/3 | 0/29 | 1/4 |
| urinary retentionRenal and urinary disorders | 0/3 | 0/29 | 1/4 |
| EpilepsyNervous system disorders | 0/3 | 2/29 | 0/4 |
| status epilepticusNervous system disorders | 0/3 | 1/29 | 0/4 |
| respiratory depressionRespiratory, thoracic and mediastinal disorders | 0/3 | 1/29 | 0/4 |
| pneumonia aspirationInfections and infestations | 0/3 | 1/29 | 0/4 |
| anaemiaBlood and lymphatic system disorders | 0/3 | 1/29 | 0/4 |
| Event | Valtoco 5mg | Valtoco 10mg | Valtoco 15mg |
|---|---|---|---|
| PyrexiaGeneral disorders | 3/3 | 4/29 | 1/4 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/3 | 6/29 | 1/4 |
| nasal congestionRespiratory, thoracic and mediastinal disorders | 1/3 | 1/29 | 0/4 |
| hypoxiaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/29 | 0/4 |
| Nasal OedemaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/29 | 0/4 |
| InfluenzaInfections and infestations | 1/3 | 1/29 | 0/4 |
| Gastroenteritis NorovirusInfections and infestations | 1/3 | 0/29 | 0/4 |
| PneumoniaInfections and infestations | 1/3 | 0/29 | 0/4 |
| SeizureNervous system disorders | 1/3 | 2/29 | 1/4 |
| VomitingGastrointestinal disorders | 1/3 | 1/29 | 0/4 |
| Age, Customized(participants) | Valtoco In Pediatric Subjects With Epilepsy |
|---|---|
| 2 to 3 years | 19 |
| 4 to 5 years | 17 |
| Sex: Female, Male(Participants) | Valtoco In Pediatric Subjects With Epilepsy |
|---|---|
| Female | 15 |
| Male | 21 |
| Ethnicity (NIH/OMB)(Participants) | Valtoco In Pediatric Subjects With Epilepsy |
|---|---|
| Hispanic or Latino | 17 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Valtoco In Pediatric Subjects With Epilepsy |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 26 |
| More than one race | 3 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | Valtoco In Pediatric Subjects With Epilepsy |
|---|---|
| United States | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2021 to primary completion in Mar 2025, 40 months.
Results were first posted in Sep 2026, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diazepam
Neurelis, Inc.